The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy
Francesca Arruga(Italian institute for Genomic Medicine), Silvia Deaglio(Department of Medical Sciences), Tiziana Vaisitti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), John N. Allan(Cornell University), Alberto Maria Todesco(University of Turin), Marta Coscia(University of Turin), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Nikolaos Ioannou(King's College London), Andrea Iannello(University of Turin), Alan G. Ramsay(King's College London), Richard R. Furman(Cornell University)
Cited by 3
Related Papers
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k